Under the agreement, initially announced in September 2015, Titan Spine provides its spinal interbody fusion devices featuring its proprietary surface technology to MBA for distribution in seven EU countries: Spain, Portugal, Andorra, Luxembourg, Belgium, the United Kingdom (UK) and now Italy.
MBA is a prominent international medical device marketing-and-distribution organization that specializes in the sale of products used for orthopedic and neurosurgery treatments.
Marcus Klarl, Vice President of Sales, Europe for Titan Spine, commented, “Our initial distribution agreement with MBA has proven largely successful over the past year due to accelerating sales growth.
“Increased surgeon adoption within the EU interbody device market has demonstrated the growing desire for surface enhanced interbody fusion devices that stimulate healing at the cellular level where it is most critical for improved patient outcomes.
We look forward to providing these benefits to spine surgeons and patients in Italy – an interbody fusion market that is projected to surpass $25 million next year.”
“Titan Spine is more than a supplier for us; they are a partner,” commented Carlos Marina, CEO for MBA.
“Since the beginning of our commercial relationship with Titan, we have worked together seamlessly. In fact, on introducing Titan Spine into the Italian market they have now become the only supplier that MBA works with in all countries where we operate: Spain, Andorra, Portugal, Belgium, UK, Luxembourg, and Italy.”
Titan Spine offers a full line of Endoskeleton devices that feature Titan Spine’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and nano levels (MMN™).
This unique combination of surface topographies is designed to create an optimal host-bone response and actively participate in the fusion process by promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth, encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and creating the potential for a faster and more robust fusion.
